Article

Mayo Clinic addresses newest treatments for pterygium

Scottsdale, AZ-The Mayo Clinic has answers to the question, "What is the newest treatment for pterygium?"

Scottsdale, AZ-The Mayo Clinic has answers to the question, "What is the newest treatment for pterygium?"

According to the clinic, although there are a new surgical methods to treat these growths, they are preventable and treatable by non-surgical methods.

Simply by using sunglasses outside, specifically UV-blocking and wraparound types, or a wide-brimmed hat can prevent pterygium.

Non-surgical treatments include over-the-counter eye drops, which are preservative-free, steroid drops, which if used too much will increase the risk of glaucoma and cataracts, and a plug that blocks the tear drains.

If surgery is necessary it is best to use an anti-metabolite called mitomycin C that retards the growth of residual cells. Another technique is to place a barrier on the site, in the form of an amniotic membrane transplant.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.